Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients

Fujiwara,Yoshinori; Yoshikawa,Reigetsu; Kamikonya,Norihiko; Nakayama,Tsuyoshi; Kitani,Kotaro; Tsujie,Masanori; Yukawa,Masao; Inoue,Masatoshi; Yamamura,Takehira

doi:10.3892/or.2012.1847

Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients

Authors:
- Yoshinori Fujiwara
- Reigetsu Yoshikawa
- Norihiko Kamikonya
- Tsuyoshi Nakayama
- Kotaro Kitani
- Masanori Tsujie
- Masao Yukawa
- Masatoshi Inoue
- Takehira Yamamura
View Affiliations

Affiliations: Department of Digestive Surgery, Nara Hospital, Kinki University School of Medicine, Nara, Japan, Department of Surgery, Kanzaki Hospital, Hyogo, Japan, Department of Radiology, Hyogo College of Medicine, Nishinomiya, Japan, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan
Published online on: June 1, 2012 https://doi.org/10.3892/or.2012.1847
Pages: 446-452
Copyright: © Fujiwara et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The prognosis of advanced esophageal cancer patients is poor. Trimodality therapy of surgical resection plus neoadjuvant chemoradiotherapy (CRT) has been developed to improve survival through locoregional control, leading to prevention of micrometastasis. We investigated whether or not neoadjuvant CRT led to survival benefits in TNM stage II/III esophageal cancer patients. We retrospectively reviewed 62 patients with stage II or III esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant CRT. All patients received esophagectomy 4-7 weeks after CRT consisting of 40 Gy irradiation and chemotherapy (5-FU, 500 mg/m2/day, days 1-5 and cisplatin, 10-20 mg/body, days 1-5). Clinical response and survival rates were analyzed using Kaplan-Meier methods, with p<0.05 considered as significant. The clinical effect rate of CRT for both primary tumors and metastatic nodes was 82.3%. Operative and hospital mortality rates were 1.65 and 6.5%, respectively. The 3-year overall survival (OS) and disease-free survival (DFS) rates were 52.6 and 49.2%, respectively. A significant difference was noted between stages II and III for both OS and DFS. The 5-year OS rates were 64.2% for stage II, 33.1% for stage III (T4 and non-T4) and 46.9% for stage III (non-T4 only) patients. The depth of tumor invasion (T3 vs. T4), resectability (R0 vs. R1, R2), lymph node metastasis (positive vs. negative), and the effect of CRT were proven to be independent prognostic factors for univariate analysis, with resectability and the effect of CRT for multivariate analysis. These data suggest that CRT in stage II/III (non-T4) ESCC patient contributed to tumor shrinkage, leading to higher resectability and longer survival. Neoadjuvant CRT appears to be a promising option for these patients.

View Figures

View References

1	Goseki N, Koike M and Yoshida M: Histopathologic characteristics of early stage esophageal carcinoma. A comparative study with gastric carcinoma. Cancer. 69:1088–1093. 1992. View Article : Google Scholar : PubMed/NCBI
2	Roth JA and Putnam JB Jr: Surgery for cancer of the esophagus. Semin Oncol. 21:453–461. 1994.PubMed/NCBI
3	Sugimachi K, Inokuchi K, Kuwano H, Kai H, Okamura T and Okudaira Y: Patterns of recurrence after curative resection for carcinoma of the thoracic part of the esophagus. Surg Gynecol Obstet. 157:537–540. 1983.PubMed/NCBI
4	Salazar JD, Doty JR, Lin JW, et al: Does cell type influence post-esophagectomy survival in patients with esophageal cancer? Dis Esophagus. 11:168–171. 1998.PubMed/NCBI
5	Ando N, Ozawa S, Kitagawa Y, Shinozawa Y and Kitajima M: Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg. 232:225–232. 2000.PubMed/NCBI
6	Earlam R and Cunha-Melo JR: Oesophogeal squamous cell carcinoms: II. A critical view of radiotherapy. Br J Surg. 67:457–461. 1980. View Article : Google Scholar : PubMed/NCBI
7	Isono K, Sato H and Nakayama K: Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology. 48:411–420. 1991. View Article : Google Scholar : PubMed/NCBI
8	Akiyama H, Tsurumaru M, Udagawa H and Kajiyama Y: Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg. 220:364–372. 1994. View Article : Google Scholar : PubMed/NCBI
9	Ozawa S, Baba H, Tachimori Y, et al: Comprehensive registry of esophageal cancer in Japan, 2003. Esophagus. 8:9–29. 2011. View Article : Google Scholar
10	International Union Against Cancer (UICC). TNM Classification of malignant Tumours. Sobin LH, Gospodarowicz MK and Wittekind C: 5th edition. John Wiley & Sons, Inc; New York: 1997
11	Kelsen DP, Ginsberg R, Pajak TF, et al: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 339:1979–1984. 1998. View Article : Google Scholar : PubMed/NCBI
12	Cooper JS, Guo MD, Herskovic A, et al: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 281:1623–1627. 1999. View Article : Google Scholar
13	Minsky BD, Pajak TF, Ginsberg RJ, et al: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 20:1167–1174. 2002. View Article : Google Scholar : PubMed/NCBI
14	Urba SG, Orringer MB, Perez-Tamayo C, Bromberg J and Forastiere A: Concurrent preoperative chemotherapy and radiation therapy in localized esophageal adenocarcinoma. Cancer. 69:285–291. 1992. View Article : Google Scholar : PubMed/NCBI
15	Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N and Hennessy TP: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 335:462–467. 1996. View Article : Google Scholar : PubMed/NCBI
16	Nygaard K, Hagen S, Hansen HS, et al: Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg. 16:1104–1110. 1992. View Article : Google Scholar
17	Le Prise E, Etienne PL, Meunier B, et al: A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer. 73:1779–1784. 1994.PubMed/NCBI
18	Apinop C, Puttisak P and Preecha N: A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology. 41:391–393. 1994.PubMed/NCBI
19	Bosset JF, Gignoux M, Triboulet JP, et al: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 337:161–167. 1997. View Article : Google Scholar : PubMed/NCBI
20	Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A and Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 19:305–313. 2001.PubMed/NCBI
21	Lee JL, Park SI, Kim SB, et al: A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol. 15:947–954. 2004. View Article : Google Scholar
22	Burmeister BH, Smithers BM, Gebski V, et al: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 6:659–668. 2005. View Article : Google Scholar : PubMed/NCBI
23	Tepper J, Krasna MJ, Niedzwiecki D, et al: Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 26:1086–1092. 2008. View Article : Google Scholar
24	Fujiwara Y, Kamikonya N, Inoue T, et al: Chemoradiotherapy for T3 and T4 squamous cell carcinoma of the esophagus using low-dose FP and radiation: a preliminary report. Oncol Rep. 14:1177–1182. 2005.PubMed/NCBI
25	Japanese Society for Esophageal Disease. Guidelines for Clinical and Pathologic Studies on Carcinoma of the Esophagus. 9th edition. Kanehara & Co., Ltd; Tokyo: 2001
26	National Cancer Institute. Cancer Therapy Evaluation Program, Common Toxicity Criteria Version 3.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. August 9–2006
27	Courrech Staal EF, Aleman BM, Boot H, van Velthuysen ML, van Tinteren H and van Sandick JW: Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg. 97:1482–1496. 2010.PubMed/NCBI
28	Keller SM, Ryan LM, Coia LR, et al: High dose chemoradiotherapy followed by esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction: results of a phase II study of the Eastern Cooperative Oncology Group. Cancer. 83:1908–1916. 1998. View Article : Google Scholar
29	De Vita F, Di Martino N, Orditura M, et al: Preoperative chemoradiotherapy for squamous cell carcinoma and adenocarcinoma of the esophagus: a phase II study. Chest. 122:1302–1308. 2002.PubMed/NCBI
30	Hsu FM, Lee JM, Huang PM, et al: Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 81:e593–e599. 2011. View Article : Google Scholar
31	Morota M, Gomi K, Kozuka T, et al: Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys. 75:122–128. 2009. View Article : Google Scholar : PubMed/NCBI
32	Onozawa M, Nihei K, Ishikura S, et al: Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. Radiother Oncol. 92:266–269. 2009. View Article : Google Scholar : PubMed/NCBI
33	Zhao KL, Ma JB, Liu G, Wu KL, Shi XH and Jiang G: Three-dimensional conformal radiation therapy for esophageal squamous cell carcinoma: is elective nodal irradiation necessary? Int J Radiat Oncol Biol Phys. 76:446–451. 2010. View Article : Google Scholar : PubMed/NCBI
34	Button MR, Morgan CA, Croydon ES, Roberts SA and Crosby TD: Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 73:818–823. 2009. View Article : Google Scholar
35	Kranzfelder M, Schuster T, Geinitz H, Friess H and Buchler P: Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg. 98:768–783. 2011. View Article : Google Scholar : PubMed/NCBI
36	Ando N, Kato H, Igaki H, et al: A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 19:68–74. 2011. View Article : Google Scholar
37	Ando N, Iizuka T, Ide H, et al: Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study - JCOG9204. J Clin Oncol. 21:4592–4596. 2003. View Article : Google Scholar : PubMed/NCBI